Pastør21 AI – Revolutionizing Infectious Disease Management

AI-powered precision diagnostics for faster, more accurate, and more actionable clinical decisions at the point of care.

Discover Our Vision Invest in the Future

Pastør 21 is fundamentally transforming how the world manages infectious disease. We are uniquely positioned to lead a new era of precision infectious disease management — delivering significant healthcare impact and investor returns.

Our Mission

To advance the field of infectious disease management through AI-powered precision diagnostics — enabling faster, more accurate, and more actionable clinical decisions at the point of care.

Our Vision

Global leader in genomic-driven infectious disease platforms — providing a scalable, clinically embedded solution that empowers health systems to stay ahead of rapidly evolving microbial threats, improve patient outcomes, and reduce healthcare costs.

Value Proposition

Unique combination of pan-genomic sequencing + explainable AI (xAI) + hospital access → actionable insights → scalable revenue streams.

Market Landscape

Global Market Size

Global Infectious Disease Diagnostics Market Size

Significant and growing market, driven by increasing prevalence of infectious diseases and demand for rapid, accurate diagnostics.

  • Market Size: $66.73 billion by 2034
  • Growth Rate: CAGR of 7.3% from 2025-2034

AMR Costs

AMR-Related Healthcare Costs Projected

Antimicrobial Resistance (AMR) poses a massive economic burden and public health threat and could result in:

  • $1 Trillion additional healthcare costs by 2050
  • $3.4 trillion GDP losses per year by 2030​
  • 10 million deaths by 2050 (WHO)

Market Drivers

Market Drivers

  • Pandemic Awareness: Heightened global understanding of infectious disease threats.
  • Stewardship Mandates: Regulatory push for responsible antimicrobial use.
  • Regulatory Shifts: Evolving policies favoring precision diagnostics.

Product Offering

Platform Architecture

  • Pan-genome analytics Analyze pathogen genomes and resistance patterns.
  • Explainable AI (xAI) layer: Turns complex multi-omic data into clear insights.
  • Actionable reports: Provides clinicians with immediate, useful information.

Core Applications

  • AMR (Antimicrobial Resistance) detection: Critical for effective treatment.
  • Virulence risk assessment: Precision for common infections.
  • Stewardship support: Optimizing antibiotic use.

Key Benefits

  • Faster Diagnosis: Accelerates clinical decision-making.
  • Improved Outcomes: Tailored treatments enhance patient recovery.
  • Hospital ROI: Reduces healthcare costs and optimizes resource allocation.

Team Overview

Bernhard

Bernhard Palsson

Co-Founder

Bernhard is an endowed Professor in the Department of Bioengineering at the UC San Diego. Dr. Palsson has co-authored more than 660 peer-reviewed research articles. His research includes the development of computational biology, genome-scale models, data analytic methods and the formulation of specific sysbio models of the red blood cell, E. coli, CHO cells, and many human pathogens. He is inventor on over 40 U.S. patents, the co-founder of several biotechnology companies, and holds several major biotechnology awards

Jonathan

Jonathan Monk

Co-Founder

Jonathan has spent 15+ years in bioinformatics and systems biology research, development and implementation.  He has published over 100 peer-reviewed publications on applications of genomics for infectious disease diagnostics and management.  Jonathan was previously funded on a $10M NIAID grant focused on systems biology of antibiotic resistance. He previously worked for Sinopia Biosciences and UC San Diego. Jonathan received his PhD from UC San Diego and his BSE from Princeton University

Rick

Rick Gannotta

Acting CEO

Biography. Dr. Richard Gannotta is a seasoned healthcare executive, educator, and innovator with extensive C-Suite experience leading major health systems, including UC Irvine Health, Duke Raleigh Hospital, and Northwestern Memorial Hospital.

Adil

Adil Mardinoglu

President

Professor Adil Mardinoglu is an expert in the field of Systems Medicine, Systems Biology, Computational Biology and Bioinformatics. He is a Professor of Systems Biology in the Centre for Host-Microbiome Interactions (CHMI), King’s College London, UK where he leads a computational group. He also works as group leader in the Science for Life Laboratory (Scilifelab), KTH-Royal Institute of Technology in Sweden and leads a team of 25 researchers working in the area of computational biology, experimental biology and drug development.

Partners

SZA Longevity Logo Pastør21 is a Joint Venture with SZA Longevity, leveraging their worldwide hospital network and expertise in genomics to enhance our capabilities.

Investment Opportunity

Partner with Pastør 21 to revolutionize infectious disease management.

Current Round Raise

We are currently raising investment to accelerate our growth and impact.

Use of Funds

Funds will fuel:

  • Product development
  • Strategic hiring
  • Regulatory approvals
  • Market scaling initiatives

Why Invest Now

The convergence of escalating antimicrobial resistance, rising healthcare costs, and global threats from emerging infectious diseases creates an urgent need and immense market opportunity for Pastør21's solution.

Contact Us for Full Investor Deck